6:17 PM
 | 
Jun 27, 2013
 |  BC Extra  |  Clinical News

Veloxis' LCP-Tacro non-inferior to Prograf in preventing organ rejection

Veloxis Pharmaceuticals A/S (CSE:VELO) said once-daily LCP-Tacro met the primary endpoint of non-inferiority to twice-daily Prograf tacrolimus from Astellas Pharma Inc. (Tokyo:4503) in the Phase III Study 3002 to prevent organ transplant rejection in...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >